✨ Free AI Report
9 Meters Biopharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research 9 Meters Biopharma, Inc.
Company Research

9 Meters Biopharma, Inc.: Business Overview, Financials & Competitive Analysis

9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.

Analyst-debate audio for 9 Meters Biopharma, Inc.

AskCyborg analysts argue the bull and bear cases for 9 Meters Biopharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
2/ 10Challenged

Cyborg Score thesis

Ceased operations with no active pipeline—investment thesis invalidated....

Read the full analyst-debate transcript →
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest 9 Meters Biopharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

9 Meters Biopharma, Inc. Overview

Pro stress-test →

9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.

Strategic Profile

Pro stress-test →

The company previously focused on developing therapies including vurolenatide for short bowel syndrome and GIP antagonist NM-136 for obesity. Its pipeline-focused business model and clinical-stage status made it dependent on successful development milestones and funding.

Competitive Landscape

Pro stress-test →

As a ceased-stage company, 9 Meters no longer competes in the market. Previously, it competed against established GI therapeutics developers and obesity drug manufacturers.

Key facts

Headquarters: Raleigh, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on 9 Meters Biopharma, Inc..

  • Company ceased operations after struggling with pipeline advancement and funding
  • Stock declined 90% over the prior year period with delisting concerns
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Compare 9 Meters Biopharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account
NEW · MCP server

Ask your AI assistant about 9 Meters Biopharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 9 Meters Biopharma, Inc. and its top competitor on Cyborg Score”
“What did 9 Meters Biopharma, Inc. do this quarter?”
“Is 9 Meters Biopharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does 9 Meters Biopharma, Inc. do?+
9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.
What is 9 Meters Biopharma, Inc.'s Cyborg Score?+
9 Meters Biopharma, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 9 Meters Biopharma, Inc.'s main competitors?+
The full competitive landscape for 9 Meters Biopharma, Inc. is in the AskCyborg report.
How can I get the full 9 Meters Biopharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 9 Meters Biopharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 9 Meters Biopharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual